STING1 and COVID-19: Research on COVID-19 vaccines has further driven interest in STING agonists as vaccine adjuvants as they can enhance immune responses to SARS-CoV-2 and provide broad and durable protective effects (Humphries et al., 2021a; Zhang Y. et al., 2023).